Novartis AG (ADR) (NYSE:NVS)

CAPS Rating: 5 out of 5

Operates in the business of patent-protected and generic pharmaceuticals as well as consumer health products.

Results 1 - 20 of 185 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar solutionorppt (< 20) Submitted: 6/19/2015 2:08:19 PM : Outperform Start Price: $100.38 NVS Score: +1.22

First company to garner FDA approval for a biosimilar, good dividends and management.

Recs

0
Member Avatar cmrk3 (37.20) Submitted: 3/21/2015 10:03:40 AM : Outperform Start Price: $102.31 NVS Score: -0.98

Barron's List World's Greatest CEOs 3/23/15 - Joseph Jimenez

Recs

0
Member Avatar oncqueen (68.61) Submitted: 8/30/2014 10:11:55 AM : Outperform Start Price: $90.78 NVS Score: +6.78

New blockbuster drug for heart failure in the works, with a 20% reduction in death vs standard rx, and a decrease in hospitalization. Buying it in the real world next market day. Dividend around 2.7%, too.

Recs

1
Member Avatar bricehobbs (< 20) Submitted: 5/14/2014 1:46:32 PM : Outperform Start Price: $87.39 NVS Score: +4.87

Dividend, M & A activity, and pipeline.

Recs

1
Member Avatar fischdoctor (67.97) Submitted: 10/28/2013 8:22:30 AM : Outperform Start Price: $75.64 NVS Score: +14.08

good solid company.

Recs

1
Member Avatar alexf (< 20) Submitted: 8/29/2013 10:36:41 AM : Outperform Start Price: $69.33 NVS Score: +18.09

Good mix of products. Good management.

Recs

1
Member Avatar wilkeh (44.39) Submitted: 6/6/2013 10:15:14 AM : Outperform Start Price: $67.68 NVS Score: +19.17

diversified healthcare company will become the largest healthcare (pharma) company in the world in terms of revenue

Recs

0
Member Avatar kbelboe2 (35.39) Submitted: 7/13/2012 11:26:25 PM : Outperform Start Price: $51.66 NVS Score: +40.11

Another Euro drug manufacturer that now does generic stuff. Cheap and about to go higher.

Recs

0
Member Avatar pphamelin (74.34) Submitted: 6/26/2012 2:30:36 PM : Outperform Start Price: $50.46 NVS Score: +41.06

lack of patent protection overhyped

Recs

0
Member Avatar allegra (58.98) Submitted: 3/12/2012 2:07:13 PM : Outperform Start Price: $50.01 NVS Score: +48.25

pharmy and generic pipeline, biotech, plus optical

Recs

0
Member Avatar renoryan100 (52.39) Submitted: 2/29/2012 10:43:28 AM : Outperform Start Price: $50.64 NVS Score: +45.95

Dividend Monk

Recs

1
Member Avatar Raufus (< 20) Submitted: 2/26/2012 10:58:52 AM : Outperform Start Price: $50.87 NVS Score: +43.79

Novartis is the world's third largest pharmaceutical company with blockbuster products such as Glivec/Tasigna (cancer) and Gilenya (multiple sclerosis). PE at 9.6 and a net dividend yield of 4.8%. The market will reflect that.

Recs

1
Member Avatar Dan22italy (27.18) Submitted: 12/19/2011 1:00:13 AM : Outperform Start Price: $50.16 NVS Score: +29.14

one of best pharma, good dividend

Recs

0
Member Avatar starbucks4ever (97.67) Submitted: 11/18/2011 2:07:58 AM : Outperform Start Price: $49.24 NVS Score: +33.43

A reasonably safe bet. The management is finished destroying value through acquisitions: the last cash that remained to be squandered has been squandered last year, and during a debt crisis nobody will lend them money for the next purchase. That leaves us with a low PE, and with speculators assuming (mistakenly) that with no more empire building the "E" will finally accrue to them. This illusion will put a floor under the price, especially when the "E" is stable and speculators are desperately looking for stability.

Recs

0
Member Avatar MojoJoe (75.85) Submitted: 9/21/2011 11:34:38 AM : Outperform Start Price: $49.70 NVS Score: +27.73

Excellent company, great dividend analysis.

Recs

0
Member Avatar clayman14 (20.44) Submitted: 9/15/2011 4:30:29 PM : Outperform Start Price: $49.93 NVS Score: +28.95

Swiss Compant + Decent Yield + Pharma

Recs

0
Member Avatar beadnell (91.16) Submitted: 8/4/2011 6:17:09 AM : Outperform Start Price: $52.73 NVS Score: +22.66

It is a good day to buy European stocks (even cheaper than when I bought it.)

Recs

0
Member Avatar Jamanji (83.90) Submitted: 7/8/2011 10:36:44 AM : Outperform Start Price: $55.61 NVS Score: +24.54

Barrons 7-4-11

Recs

0
Member Avatar utri (< 20) Submitted: 7/1/2011 11:44:37 AM : Outperform Start Price: $54.31 NVS Score: +28.05

Has exposure to both patented and generic medicine.
Good balance sheet.
Should move up after Alcon acquisition is complete.

Recs

0
Member Avatar FuriousGreen (92.41) Submitted: 5/2/2011 2:20:51 PM : Outperform Start Price: $52.92 NVS Score: +36.66

Solid in recession, solid outside of recession.

Featured Broker Partners


Advertisement